REPLICATION COMPETENT RETROVIRUS TESTING (RCR) IN THE NATIONAL GENE VECTOR BIOREPOSITORY: NO EVIDENCE OF RCR IN 1595 POST-TREATMENT PERIPHERAL BLOOD SAMPLES OBTAINED FROM 60 CLINICAL TRIALS

By sjmartinez • December 16, 2022

Cornetta K, Yao J, House K, Duffy L, Adusumilli PS, Beyer R, Booth C, Brenner M, Curran K, Grilley B, Heslop H, Hinrichs CS, Kaplan RN, Kiem HP, Kochenderfer J, Kohn DB, Mailankody S, Norberg SM, O'Cearbhaill RE, Pappas J, Park J, Ramos C, Ribas A, Rivièra I, Rosenberg SA, Sauter C, Shah N, Slovin SF, Thrasher A, Williams DA, Lin TY. REPLICATION COMPETENT RETROVIRUS TESTING (RCR) IN THE NATIONAL GENE VECTOR BIOREPOSITORY: NO EVIDENCE OF RCR IN 1595 POST-TREATMENT PERIPHERAL BLOOD SAMPLES OBTAINED FROM 60 CLINICAL TRIALS. Mol Ther. 2022 Dec 13:S1525-0016(22)00710-9. doi: 10.1016/j.ymthe.2022.12.006. Epub ahead of print. PMID: 36518078.

Tags: Hematology/Oncology, Publications

Related Posts

Linking Baseline PSMA PET-Derived Parameters to Toxicity, Adverse Events, Pain, and Quality of Life in Patients Treated with [177Lu]Lu-PSMA-617: A Single-Center Retrospective Study

Murthy V, Kimura K, Theus L, Nguyen A, Grogan TR, Lokre O, Perk T, Rettig MB, Drakaki A, Shen J, Thin P, Nguyen K, Lira[...]

Neoadjuvant modified FOLFIRINOX plus nivolumab in borderline-resectable pancreatic ductal adenocarcinoma: a pilot phase 1 trial

Wainberg ZA, Link JM, Premji A, Zheng S, Srienc M, Hammons M, Kim SE, Li L, Liu Z, Tsvetkova O, Abt ER, Rosen L, Kim[...]

Clinical and translational results from a phase 1 trial of gemcitabine/nab-paclitaxel with nivolumab/ipilimumab or hydroxychloroquine/ipilimumab in untreated metastatic pancreatic adenocarcinoma

O'Reilly EM, Cabanski CR, Lyman JP, Wainberg ZA, Fisher GA, Wolff RA, Ko AH, O'Hara MH, Spencer CN, Yu JX, Da Silva DM, Padrón LJ,[...]